Portopulmonary Hypertension Clinical Trial
Official title:
Ambrisentan for Treatment of Portopulmonary Hypertension (PoPH): a Pilot Study
Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension
and is present in approximately 5% of cirrhotic patients. Treatment options include
prostanoids, sildenafil, and the endothelin-receptor antagonists, bosentan and ambrisentan.
This study investigates the safety and efficacy of ambrisentan in portopulmonary
hypertension.
Patients with clinically significant PoPH (resting mean pulmonary arterial pressure >25 mm Hg, pulmonary vascular resistance >400 dynes*s*cm-5) will be offered treatment with ambrisentan. Patients will be followed clinically and hemodynamically up to 12 months after start of treatment. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03309592 -
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
|
Phase 4 | |
| Completed |
NCT01028651 -
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
|
N/A | |
| Terminated |
NCT01517854 -
Revatio Portal-Pulmonary Arterial Hypertension Trial
|
Phase 2 | |
| Completed |
NCT01224210 -
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
|
Phase 3 | |
| Completed |
NCT02382016 -
PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
|
Phase 4 |